These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 20635916)
21. [Current treatment of follicular lymphoma]. Bonnet C; Beguin Y; Deprijck B; de Leval L; Fillet G Rev Med Suisse; 2009 Aug; 5(214):1663-7. PubMed ID: 19772198 [TBL] [Abstract][Full Text] [Related]
22. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688 [TBL] [Abstract][Full Text] [Related]
23. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. Zinzani PL; d'Amore F; Bombardieri E; Brammer C; Codina JG; Illidge T; Jurczak W; Linkesch W; Morschhauser F; Vandenberghe E; Van Hoof A Eur J Cancer; 2008 Feb; 44(3):366-73. PubMed ID: 18194857 [TBL] [Abstract][Full Text] [Related]
24. Obinutuzumab in follicular lymphoma. Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536 [TBL] [Abstract][Full Text] [Related]
25. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma. Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633 [TBL] [Abstract][Full Text] [Related]
26. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Grillo-López AJ Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055 [TBL] [Abstract][Full Text] [Related]
27. Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab. Cohen Y; Libster D; Da'as N; Amir G; Polliack A Hematol J; 2003; 4(2):151-3. PubMed ID: 12750735 [TBL] [Abstract][Full Text] [Related]
28. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028 [TBL] [Abstract][Full Text] [Related]
30. Treatment strategies in advanced stage follicular lymphoma. van Oers MH; Kersten MJ Best Pract Res Clin Haematol; 2011 Jun; 24(2):187-201. PubMed ID: 21658618 [TBL] [Abstract][Full Text] [Related]
31. Rituximab for the treatment of follicular lymphoma. Cheah CY; Lingaratnam S; Seymour JF Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675 [TBL] [Abstract][Full Text] [Related]
32. Current status and perspective of antibody therapy in follicular lymphoma. Buske C; Weigert O; Dreyling M; Unterhalt M; Hiddemann W Haematologica; 2006 Jan; 91(1):104-12. PubMed ID: 16434378 [TBL] [Abstract][Full Text] [Related]
34. Rituximab in the therapy of stage III and IV follicular lymphoma: Results of the REFLECT 1 study of the Serbian Lymphoma Group. Popovic S; Jovanovic D; Mihaljevic B; Andjelkovic N; Marjanovic G; Marisavljevic D; Vlaisavljevic N; Popovic L; Salma S; Agic D; Milosevic R; Smiljanic M; Sretenović S; Djurdjević P; Markovic O; Hajder J; Govedarovic N J BUON; 2017; 22(2):487-494. PubMed ID: 28534374 [TBL] [Abstract][Full Text] [Related]
35. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. DeMonaco NA; Jacobs SA Clin Nucl Med; 2007 Dec; 32(12):933-4. PubMed ID: 18030044 [TBL] [Abstract][Full Text] [Related]
36. What is the role of maintenance rituximab in follicular NHL? Maloney DG Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281 [TBL] [Abstract][Full Text] [Related]
37. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. Mozessohn L; Cheung MC; Crump M; Buckstein R; Berinstein N; Imrie K; Kuruvilla J; Piliotis E; Kukreti V Leuk Lymphoma; 2014 Nov; 55(11):2502-7. PubMed ID: 24450580 [TBL] [Abstract][Full Text] [Related]
38. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Jäger U; Fridrik M; Zeitlinger M; Heintel D; Hopfinger G; Burgstaller S; Mannhalter C; Oberaigner W; Porpaczy E; Skrabs C; Einberger C; Drach J; Raderer M; Gaiger A; Putman M; Greil R; Haematologica; 2012 Sep; 97(9):1431-8. PubMed ID: 22511498 [TBL] [Abstract][Full Text] [Related]
39. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705 [TBL] [Abstract][Full Text] [Related]
40. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Leonard JP Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]